Stool DNA testing to screen for colorectal cancer in the medicare population: A cost-effectiveness analysis

Annals of Internal Medicine

Volumn 153, Issue 6, 2010, Pages 368-377

  Lansdorp Vogelaar, Iris ^a   Kuntz, Karen M ^b   Knudsen, Amy B ^c   Wilschut, Janneke A ^a   Zauber, Ann G ^d   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SCREENING; CLINICAL EVALUATION; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA FINGERPRINTING; DRUG COST; HUMAN; MEDICAID; MEDICARE; OCCULT BLOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ADENOMA; CARCINOMA; CHEMISTRY; COLORECTAL TUMOR; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; FECES; MASS SCREENING; MIDDLE AGED; REIMBURSEMENT; SENSITIVITY AND SPECIFICITY; UNITED STATES;

DNA;

ADENOMA; AGED; CARCINOMA; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; FECES; HUMANS; MASS SCREENING; MEDICARE; MIDDLE AGED; REIMBURSEMENT MECHANISMS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 77957356215     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-6-201009210-00004     Document Type: Article

References (60)

1. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441-50, W81. [PMID: 18838724]
2. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103:2862-70. [PMID: 18759824]
3. Chung DC. Stool DNA testing and colon cancer prevention: another step forward [Editorial]. Ann Intern Med. 2008;149:509-10. [PMID: 18838731]
4. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-61. [PMID: 11035892]
5. Knudsen A. Explaining secular trends in colorectal cancer incidence and mortality with an empirically-calibrated microsimulation model [PhD dissertation]. Cambridge: Harvard University; 2005.
6. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999;32:13-33. [PMID: 10066353]
7. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst. 2000;92:557-63. [PMID: 10749911] (Pubitemid 30212317)
8. Arminski TC, Mclean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum. 1964;7:249-61. [PMID: 14176135]
9. Blatt L. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum. 1961;4:277-282.
10. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer. 1988;61:1472-6. [PMID: 3345499]
11. Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963;157:223-6. [PMID: 14020146]
12. Clark JC, Collan Y, Eide TJ, Estève J, Ewen S, Gibbs NM, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985;36:179-86. [PMID: 4018911] (Pubitemid 15243443)
13. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer. 1986;38:173-6. [PMID: 3733258]
14. Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut. 1992;33:1508-14. [PMID: 1452076]
15. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol. 1989;24:799-806. [PMID: 2799283] (Pubitemid 19226933)
16. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979;43:1847-57. [PMID: 445371] (Pubitemid 9203736)
17. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982;49:819-25. [PMID: 7055790] (Pubitemid 12165443)
18. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982;23:835-42. [PMID: 7117903]
19. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Public Use. Nov 2003 Sub (1973-2001), DCCPS, Surveillance Research Program, Cancer Statistics Branch. Based on the November 2003 submission. Bethesda, MD: National Cancer Institute. Accessed at www.seer.cancer.gov on 5 March 2010.
20. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115:2410-9. [PMID: 19288570]
21. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603-7. [PMID: 11096167] (Pubitemid 32162983)
22. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-7. [PMID: 10070942] (Pubitemid 29128279)
23. Colorectal cancer screening tests: conditions for and limitations on coverage. In: 62 Federal Register 59100; 31 October 1997,
24. as amended at 66 FR 55329; 1 November 2001;
25. 67 Federal Regulations 80040; 31 December 2002.
26. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al; American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570-95. [PMID: 18384785]
27. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56:11-25; quiz 49-50. [PMID: 16449183] (Pubitemid 43228384)
28. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;149(9).
29. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124:544-60. [PMID: 12557158]
30. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, et al; US Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130:1872-85. [PMID: 16697750]
31. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-14. [PMID: 15616205]
32. Syngal S, Stoffel E, Chung D, Willett C, Schoetz D, Schroy P, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006;106:277-83. [PMID: 16342248] (Pubitemid 43100434)
33. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003;3:47-53. [PMID: 12777192]
34. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn. 2004;6:386-95. [PMID: 15507679] (Pubitemid 39517408)
35. Perrone M. Government officials will consider paying for Exact Sciences colon cancer screening test. Associated Press Financial Wire, Business News; 2007.
36. van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. 2003. Accessed at www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=20 on 5 November 2008.
37. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462-70. [PMID: 17895475]
38. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol. 2007;102:2259-64. [PMID: 17617203]
39. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422-8. [PMID: 16083699]
40. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343-50. [PMID: 16454841]
41. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111-7. [PMID: 17161655]
42. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications of screening flexible sigmoidoscopy. Gastroenterology. 2002;123:1786-92. [PMID: 12454834]
43. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006;145:880-6. [PMID: 17179057]
44. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343:162-8. [PMID: 10900274]
45. Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007;39:168-73. [PMID: 17327977]
46. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863-72. [PMID: 17079760]
47. Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849-57, W152. [PMID: 19528563]
48. Zauber A, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007. Accessed at www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=52 on 5 March 2010.
49. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630-41. [PMID: 18445825]
50. Gold M, Siegel JE, Russell LB, Weinstein MG, eds. Cost-Effectiveness in Health and Medicine New York: Oxford Univ Pr; 1996.
51. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17:1623-30. [PMID: 18628413]
52. Mark DH. Visualizing cost-effectiveness analysis [Editorial]. JAMA. 2002;287:2428-9. [PMID: 11988064]
53. Schroy PC 3rd, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med. 2005;28:208-14. [PMID: 15710277]
54. Schroy PC 3rd, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care. 2007;13:393-400. [PMID: 17620034]
55. Exact Sciences Corporation. Exact Sciences Corporation Annual Report on Form 10-K; 2010. Accessed at www.faqs.org/sec-filings/100312/EXACT-SCIENCES- CORP-10-K/ on 26 May 2010.
56. U.S. Census Bureau. U.S. Population Projections. Accessed at www.census.gov/population/www/projections/files/nation/download/NP2008-D1.xls on 26 May 2010.
57. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126:1270-9. [PMID: 15131787]
58. Wu GH, Wang YM, Yen AM, Wong JM, Lai HC, Warwick J, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer. 2006;6:136. [PMID: 16723013]
59. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology. 1990;98:371-9. [PMID: 2403953]
60. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-30. [PMID: 17204026]